Janux Therapeutics, Inc. (JANX) Institutional Ownership

Ownership Summary

Recent 13F filings as of September 2025 show that 170 institutional investors hold a position in Janux Therapeutics, Inc. (NASDAQ:JANX).

• The collective stake of institutional investors in Janux Therapeutics moved to 108.5% in September 2025, a shift down from the 109.8% reported for June 2025.
• Institutional share ownership changed by 2.82% QoQ, while the number of institutional owners saw an increase of 6.92% YoY.
• During the quarter, 77 institutions bought more Janux Therapeutics shares, 65 sold shares, and 28 of the 170 total investors held their position steady.
• The total number of shares held by institutions in Janux Therapeutics increased to 65.18Mn as of September 2025, a net change of up by 1.79Mn shares quarter on quarter, and up 19.63Mn shares year over year.
• As of September 30, 2025, RA CAPITAL MANAGEMENT, L.P. held Janux Therapeutics's largest shareholding position with over 11.19Mn shares, representing 18.62% of total outstanding shares.
• Among the most significant buyers of Janux Therapeutics during September 2025 were T. Rowe Price Investment Management, Inc. (972.69K), ORBIMED ADVISORS LLC (555.80K), STATE STREET CORP (503.36K), TANG CAPITAL MANAGEMENT LLC (500.00K), BlackRock, Inc. (328.15K).
• Leading sellers of Janux Therapeutics stock in September 2025 included Caption Management, LLC (849.01K), Cormorant Asset Management, LP (650.00K), PRICE T ROWE ASSOCIATES INC /MD/ (527.87K), Point72 Asset Management, L.P. (433.70K), BANK OF AMERICA CORP /DE/ (365.97K).
• The top 10 institutional holders of Janux Therapeutics for the quarter ending September 2025 included RA CAPITAL MANAGEMENT, L.P. (11.19Mn), FMR LLC (9.06Mn), JANUS HENDERSON GROUP PLC (4.70Mn), BlackRock, Inc. (3.73Mn), Paradigm Biocapital Advisors LP (2.92Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.77Mn), VANGUARD GROUP INC (2.42Mn), STATE STREET CORP (1.89Mn), ORBIMED ADVISORS LLC (1.77Mn), Point72 Asset Management, L.P. (1.71Mn).